Indivior (NASDAQ:INDV) Releases Quarterly Earnings Results, Beats Estimates By $4.86 EPS

Indivior (NASDAQ:INDV) announced its quarterly earnings data on Monday. The company reported $5.75 EPS for the quarter, beating the consensus estimate of $0.89 by $4.86, FiscalAI reports. The firm had revenue of $343.00 million during the quarter, compared to analyst estimates of $307.55 million. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%.

Indivior Price Performance

Indivior stock opened at $40.01 on Monday. Indivior has a 52 week low of $19.31 and a 52 week high of $42.81. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of 20.52 and a beta of 0.86. The stock has a 50-day moving average price of $39.18 and a 200 day moving average price of $35.49.

Analysts Set New Price Targets

INDV has been the topic of several research analyst reports. Barclays began coverage on shares of Indivior in a research report on Thursday, June 18th. They set an “overweight” rating and a $46.00 target price on the stock. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Finally, Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.67.

Insider Buying and Selling

In related news, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the transaction, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. This represents a 8.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. This represents a 11.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Quarry LP acquired a new position in Indivior during the third quarter valued at $26,000. Raymond James Financial Inc. acquired a new stake in Indivior during the 2nd quarter worth about $26,000. Aquatic Capital Management LLC purchased a new position in shares of Indivior during the 3rd quarter valued at about $104,000. Landscape Capital Management L.L.C. purchased a new position in shares of Indivior during the 4th quarter valued at about $205,000. Finally, Virtus Advisers LLC acquired a new position in shares of Indivior in the 4th quarter valued at about $215,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.